Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts)

被引：0

作者：

Skrickova, Jana

Bortlicek, Zdenek

Hejduk, Karel

Pesek, Milos

Kolek, Vitezslav

Koubkova, Leona

Tomiskova, Marcela

Roubec, Jaromir

Zatloukal, Petr

Salajka, Frantisek

机构：

[1] Univ Hosp Brno, Dept Resp Dis & TB, Brno, Czech Republic

[2] Masaryk Univ Brno, Inst Biostat & Anal, Brno, Czech Republic

[3] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic

[4] Univ Hosp Praha Bulovka, Dept Pneumol, Prague, Czech Republic

[5] Univ Hosp Olomouc, Dept Pneumolgy, Olomouc, Czech Republic

[6] Univ Hosp Praha Motol, Dept Pneumol, Prague, Czech Republic

[7] Univ Hosp Hradec Kralove, Univ Hosp Ostrava Poruba, Dept Pneumol, Hradec Kralove, Czech Republic

来源：

LUNG CANCER | 2012年 / 77卷

关键词：

D O I：

10.1016/j.lungcan.2012.05.074

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S38 / S38

页数：1

共 50 条

[1] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
Silva, S.
Colquitt, J.
Hatton, M. Q.
Mohanamurali, J.
Lee, C.
Danson, S.
Fisher, P.
Woll, P.
[J]. LUNG CANCER, 2014, 83 : S13 - S13
[2] Pemetrexed in first-line treatment of non-small cell lung cancer
Esteban, Emilio
Casillas, Marta
Cassinello, Alejo
[J]. CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
[3] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N.
Bagust, A.
McLeod, C.
Greenhalgh, J.
Boland, A.
Dundar, Y.
Dickson, R.
Smith, C. Tudur
Davis, H.
Green, J.
Pearson, M.
[J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
[4] Pemetrexed for treatment of advanced non-small cell lung cancer
Fossella, FV
[J]. SEMINARS IN ONCOLOGY, 2004, 31 (01) : 100 - 105
[5] Pemetrexed in second line treatment of non-small cell lung cancer - The Portuguese experience
Araujo, A.
Barata, F.
Parente, B.
Rego, S.
Teixeira, E.
Melo, M.
Queiroga, H.
Cunha, J.
Duarte, J.
Coelho, A.
[J]. REVISTA PORTUGUESA DE PNEUMOLOGIA, 2008, 14 : S9 - S20
[6] The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)
Skrickova, Jana
Bortlicek, Zdenek
Hejduk, Karel
Pesek, Milos
Zatloukal, Petr
Kolek, Vitezslav
Salajka, Frantisek
Koubkova, Leona
Coupkova, Helena
Zemanova, Milada
[J]. LUNG CANCER, 2012, 77 : S38 - S38
[7] Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic
Skrickova, Jana
Hejduk, Karel
Bortlicek, Zbynek
Pesek, Milos
Kolek, Vitezslav
Koubkova, Leona
Zatloukal, Petr
Salajka, Frantisek
Zemanova, Milada
Sixtova, Dimka
Roubec, Jaromir
Coupkova, Helena
[J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40
[8] Pemetrexed for the treatment of non-small cell lung cancer
Genova, Carlo
Rijavec, Erika
Truini, Anna
Coco, Simona
Sini, Claudio
Barletta, Giulia
Dal Bello, Maria Giovanna
Alama, Angela
Savarino, Grazia
Pronzato, Paolo
Boccardo, Francesco
Grossi, Francesco
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (11) : 1545 - 1558
[9] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
An, Chaolun
Zhang, Jiajun
Chu, Hongjun
Gu, Chunyan
Xiao, Feng
Zhu, Fengwei
Lu, Rujian
Shi, Hai
Zhang, Hongfei
Yi, Xin
[J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
[10] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
Pu Xiaolin
Wang Jun
Li Wei
Lu Binbin
Wang Zhaoxia
Yang Min
Fan Weifei
[J]. JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209

← 1 2 3 4 5 →